Breakwater Capital Group Reduces Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Breakwater Capital Group decreased its stake in Novo Nordisk A/S (NYSE:NVO) by 10.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,555 shares of the company’s stock after selling 300 shares during the quarter. Breakwater Capital Group’s holdings in Novo Nordisk A/S were worth $220,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of NVO. Brown Brothers Harriman & Co. lifted its stake in shares of Novo Nordisk A/S by 52.3% during the 2nd quarter. Brown Brothers Harriman & Co. now owns 35,679 shares of the company’s stock worth $5,093,000 after acquiring an additional 12,257 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Novo Nordisk A/S by 2.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 77,494 shares of the company’s stock valued at $11,061,000 after purchasing an additional 1,860 shares in the last quarter. Citizens Financial Group Inc. RI raised its position in Novo Nordisk A/S by 1.0% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 14,038 shares of the company’s stock valued at $2,004,000 after purchasing an additional 134 shares in the last quarter. Pekin Hardy Strauss Inc. raised its position in Novo Nordisk A/S by 20.1% during the 2nd quarter. Pekin Hardy Strauss Inc. now owns 7,165 shares of the company’s stock valued at $1,023,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Alpha Financial Partners LLC raised its position in Novo Nordisk A/S by 8.1% during the 2nd quarter. Alpha Financial Partners LLC now owns 1,739 shares of the company’s stock valued at $248,000 after purchasing an additional 130 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 4.0 %

Shares of NVO stock opened at $81.27 on Wednesday. Novo Nordisk A/S has a 1-year low of $80.05 and a 1-year high of $148.15. The stock’s fifty day moving average price is $99.26 and its 200 day moving average price is $118.18. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market cap of $364.70 billion, a price-to-earnings ratio of 26.30, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on NVO shares. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.